STAA — STAAR Surgical Company stock price, charts and financials

QT31STAAR Surgical Company

STAAR Surgical Company (NASDAQ: STAA) is a Healthcare company in the Medical - Instruments & Supplies industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
21.24
-1.17-5.22%
STAAQT31STAAR Surgical Company·NASDAQ
21.24-5.22%
TA
Loading chart...
Screen all →
Snapshot
Index-P/E-EPS (ttm)0.08Insider Own35.12%Shs Outstand49.79MPerf Week-5.12%
Market Cap1.12BForward P/E41.47EPS next Y0.54Insider Trans0.00%Shs Float49.39MPerf Month-6.97%
Enterprise Value964.76MPEG7.16EPS next Q0.20Inst Own-Short Float8.63%Perf Quarter-22.51%
Income4.00MP/S3.27EPS this Y255.36%Inst Trans-Short Ratio5.12Perf Half Y25.55%
Sales341.00MP/B3.06EPS next Y90.07%ROA0.81%Short Interest4.26MPerf YTD-2.94%
Book/sh7.33P/C6.16EPS next 5Y39.12%ROE1.08%52W High33.99 -37.52%Perf Year-19.01%
Cash/sh3.64P/FCF-EPS past 3/5Y-ROIC1.90%52W Low14.78 43.75%Perf 3Y-49.76%
Dividend Est.-EV/EBITDA31.12Sales past 3/5Y-5.59% 7.95%Gross Margin76.23%Volatility4.19% 4.12%Perf 5Y-85.55%
Dividend TTM-EV/Sales2.83EPS Y/Y TTM119.51%Oper. Margin10.32%ATR (14)1.08Perf 10Y152.08%
Dividend Ex-Date-Quick Ratio4.03Sales Y/Y TTM8.60%Profit Margin1.13%RSI (14)41.02Recom2.88
Dividend Gr. 3/5Y-Current Ratio4.66EPS Q/Q147.13%SMA20-3.14%Beta1.16Target Price31.50
Payout0.00%Debt/Eq0.09Sales Q/Q113.64%SMA50-8.05%Rel Volume0.79Prev Close22.41
Employees921LT Debt/Eq0.09EarningsNov 04SMA200-6.30%Avg Volume904.63KPrice21.24
IPO DateFeb 24, 1992Option/ShortYes / YesEPS/Sales Surpr.-27.72% 3.24%Net Debt/EBITDA-3.51Volume711,048Change-5.22%
Analyst Ratings
DateActionAnalystRatingTarget
Aug-17-26ReiteratedUBSSell$19$28
Aug-13-26ReiteratedJefferiesBuy$60$28
Aug-13-26ReiteratedWilliam BlairMarket Perform$45$33
Aug-13-26ReiteratedUBSSell$19
May-14-26ReiteratedStifel Nicolaus$18$31
May-14-26ReiteratedMizuhoNeutral$27
May-14-26ReiteratedCanaccord GenuityBuy$27$32
May-14-26ReiteratedPiper SandlerNeutral$33
May-14-26UpgradeWedbushNeutralOutperform$26$40
Apr-09-26UpgradeCanaccord GenuityHoldBuy$22$27
Latest News· Times ET
Sep-14-26
Sep-10-26
Sep-08-26
Sep-03-26
Sep-02-26
Aug-26-26
Aug-17-26
Aug-14-26
Aug-13-26
Aug-12-26
Aug-12-2606:05PM
Aug-05-26
Company

STAAR Surgical Company, along with its subsidiaries, specializes in ophthalmological solutions, focusing on the design, development, manufacturing, and commercialization of implantable lenses for vision correction, complete with the sophisticated delivery systems necessary for their implantation. A core offering is the Visian implantable Collamer lens (ICL) product line, designed to correct various visual impairments including myopia (nearsightedness), hyperopia (farsightedness), astigmatism, and presbyopia (age-related loss of near vision). Specifically, their Hyperopic ICL addresses farsightedness. Furthermore, STAAR Surgical provides preloaded silicone intraocular lenses and associated injector systems, crucial for cataract surgery. The company also sells various injector components and ancillary medical instruments and devices. Its market outreach extends to a diverse array of healthcare providers, such as ophthalmic surgeons, specialized vision and surgical centers, hospitals, governmental healthcare facilities, and distributors. These products are predominantly utilized by ophthalmologists. Sales are conducted directly via its own sales force in key countries like the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore. In other significant markets, including China, Korea, India, France, the Benelux region, Italy, and other international territories, the company employs a hybrid sales model, leveraging both its direct representatives and independent distributors. Founded in 1982, STAAR Surgical Company is headquartered in Lake Forest, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
FY 2025
1/2/2026
FY 2024
12/27/2024
FY 2023
12/29/2023
FY 2022
12/30/2022
FY 2021
12/31/2021
FY 2020
1/1/2021
FY 2019
1/3/2020
FY 2018
12/28/2018
Total Revenue341239314
Cost of Goods Sold Incl. D&A815774
Gross Profit260182240
Selling, General and Administrative Excl. Other179188198
Research and Development384054
Other Operating Expense
700
Operating Income34-46-13
Interest Expense
000
Unusual Expense
Non-Operating Income (Expense)-18-364
Net Income Before Taxes17-82-9
Income Taxes14-211
Consolidated Net Income4-80-20
Net Income From Continuing Operations4-80-20
Net Income4-80-20
EPS (Recurring)0.08-1.62-0.41
EPS (Basic, Before Extraordinaries)0.08-1.62-0.41
EPS (Diluted)0.08-1.62-0.41
EBITDA31-74-2
Other After Tax Adjustments
Stock Option Compensation Expense
Price To Earnings Ratio
265.50
Price To Sales Ratio3.114.943.78
Gross Margin76.2576.1576.43
Operating Margin9.97-19.25-4.14
Net Margin1.17-33.47-6.37
Shares Outstanding505049
Market Capitalization1,0621,1801,186
Operating Lease Expense
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$35.93$30.32$24.72$19.12$13.51 Close Price0.00M10.27M20.53M30.80M41.06MUSD Trades VolumeSepOctNovDec2026FebMarAprMayJunJulAugSep
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Foust WarrenPresident and CEOAug 14 '26Option Exercise0.0021,994097,553Aug 18
ANDREWS DEBORAH JChief Financial Officer & EVPAug 14 '26Option Exercise0.0010,466041,452Aug 18
Michna MagdaChief Development OfficerAug 14 '26Option Exercise2.1813,19828,79843,599Aug 18
ANDREWS DEBORAH JChief Financial Officer & EVPJul 31 '26Option Exercise0.0020,787046,915Aug 04
Foust WarrenPresident and CEOJul 31 '26Option Exercise0.0020,787097,132Aug 04
ANDREWS DEBORAH JChief Financial Officer & EVPJun 25 '26Option Exercise0.0013,955032,608Aug 04
Butcher Arthur CDirectorJun 18 '26Option Exercise0.005,34109,549Jun 22
SILVERMAN LOUDirectorJun 18 '26Option Exercise0.0010,683011,158Jun 22
Jiang WeiDirectorJun 18 '26Option Exercise0.0010,683077,127Jun 22
ANDREWS DEBORAH JInterim Co-CEO and CFOMay 15 '26Option Exercise0.0015,699015,699May 19
Foust WarrenInterim Co-CEO and Pres. & COOMay 15 '26Option Exercise0.0032,990032,990May 19
Michna MagdaChief Development OfficerMay 15 '26Option Exercise0.0019,795019,795May 19
Michna MagdaChief Development OfficerMar 14 '26Option Exercise0.0017,595036,001Mar 16
Foust WarrenInterim Co-CEO and Pres. & COOMar 14 '26Option Exercise0.0029,325063,588Mar 16
Foust WarrenInterim Co-CEO and Pres. & COOMar 12 '26Option Exercise0.008,175034,263Mar 16
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.